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The growth of the biotechnology industry and the advent of the
Human Genome Project (the "HGP") have been accompanied by an
increasing number of patent applications claiming deoxyribonucleic
acid ("DNA") compounds on the basis of a novel base sequence
("DNA sequence claims").2 Between 1980 and 1997, inventors filed
about 5000 applications claiming complete gene sequences in the
United States, resulting in more than 1500 patents.3 In addition, 350
applications, covering 500,000 partial gene sequences, were pending.
At the end of 1998, Incyte Pharmaceuticals, Inc. of Palo Alto,
California, reported that it had filed applications covering 1.2 million
partial gene fragments.
4
DNA molecules are complex chemical compounds. Although
novel chemical compounds have been traditionally considered
patentable, DNA sequence patents have raised much controversy.5
Proponents of DNA patenting claim that such protection is essential
if innovative research is to be converted into new drugs, vaccines and
* J.D. Candidate, Chicago-Kent College of Law, 1999. I wish to thank Professor Lori
Andrews and Professor Dorothy Nelkin for their guidance throughout the writing and editing
process.
1. The "single-stranded" DNA molecule consists of a chain of alternating sugar residues
and phosphate groups with one of four nitrogenous bases bound to each sugar residue: adenine
(A), cytosine (C), guanine (G) or thymine (T). See ROBERT SCHLEIF, GENETICS AND
MOLECULAR BIOLOGY 22 (Johns Hopkins Univ. Press 1993) (1986). "Double-stranded" DNA
is formed by the non-covalent linking of the bases of two "complementary" DNA strands to
form a spiral ladder. See id. The pairing of bases is always such that A pairs only with T, and C
only with G. See id.
2. See S.M. Thomas et al., Ownership of the Human Genome, 380 NATURE 387, 387-88
(1996). Between 1981 and 1995, a total of 1175 patents for human DNA sequences alone have
been granted worldwide. See id. at 387.
3. See Eliot Marshall, Companies Rush to Patent DNA, 275 SCIENCE 780, 780-81 (1997).
4. See Incyte Pharmaceuticals, Inc., Incyte Issued First EST Gene Patent (visited June 29,
1999) <http://www.incyte.com/news/1998/PR9829-estpatent.html>.
5. See, e.g., Leslie Roberts, NIH Gene Patents, Round Two, 255 SCIENCE 912, 912-13
(1992).
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diagnostic tests. 6 However, those who oppose such protection claim
that the patenting of DNA sequences will destroy research
collaboration and slow down the development of future products.7
Others object to the patenting of "life," including DNA sequences,
upon moral grounds, 8 or claim that such patent protection may violate
a property right of the individuals donating the original DNA
samples.9 In addition, some object to the patenting of plant and
animal genes found in Third World countries in the absence of a
mechanism to share the wealth generated by such patents. 10
This Note examines the controversies surrounding the patenting
of the breast cancer susceptibility genes, BRCA1 and BRCA2, as well
as Expressed Sequence Tags ("ESTs"). In doing so, it discusses how
patenting standards apply to DNA and how the patent system has
dealt with the particular issues raised by attempts to patent partial
and whole genes.
I. GENE PATENTING CONTROVERSIES
The availability of automated sequencing technology" has
resulted in efforts to sequence the DNA of both the human genome 12
and the genomes of various nonhuman species. 3 In addition, the
discovery of genetic links to diseases such as breast cancer, 14 colon
cancer 5 and Huntington's disease, 6 has led to efforts to identify the
6. See George Poste, The Case for Genomic Patenting, 378 NATURE 534, 534-36 (1995).
7. See Leslie Roberts, Scientists Voice Their Opposition, 256 SCIENCE 1273, 1273 (1992).
8. See Ronald Cole-Turner, Religion and Gene Patenting, 270 SCIENCE 52, 52 (1995)
(discussing a statement issued at a press conference by a group of religious leaders that "humans
and animals are creations of God, not humans, and as such should not be patented as human
inventions").
9. See David Dickson, Whose Genes Are They Anyway?, 381 NATURE 11, 11, 13-14 (1996)
(discussing plans by the Human Genome Diversity Project to collect DNA samples from 500
linguistically distinct groups throughout the world to determine the extent of genetic variation
in the human race).
10. See Neil Gross & John Carey, Who Owns the Tree of Life?, Bus. WK., Nov. 4, 1996, at
194, 194.
11. See generally AUTOMATED DNA SEQUENCING AND ANALYSIS (Mark D. Adams et al.
eds., 1994) (reviewing the state of the art of DNA sequence analysis).
12. See, e.g., W.R. McCombie et al., Expressed Genes, Alu Repeats and Polymorphisms in
Cosmids Sequenced from Chromosome 4p16.3, 1 NATURE GENETICS 348, 348 (1992)
(describing the sequencing of part of the Huntington's disease region in chromosome four).
13. See, e.g., Claire O'Brien, Entire E. Coli Genome Sequenced-at Last, 385 NATURE 472,
472 (1997) (discussing the completion of sequencing of the bacterium Escherichia coli).
14. See Jeff M. Hall et al., Linkage of Early-Onset Familial Breast Cancer to Chromosome
17q21, 250 SCIENCE 1684, 1684 (1990).
15. See Gloria M. Peterson et al., Presymptomatic Direct Detection of Adenomatous
Polyposis Coli (APC) Gene Mutations in Familial Adenomatous Polyposis, 91 HUM. GENETICS
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particular genes that cause this susceptibility. The identification of
such genes has often been followed by attempts to patent these
discoveries. Many object to such patents for a variety of reasons,
illustrated by two controversies. The legal and technical arguments
surrounding attempts to patent BRCA1, BRCA2 and ESTs
encompass the viewpoints of both those who support and oppose
attempts to patent newly discovered DNA sequences.
A. Gene Hunting- The Search for the Breast Cancer Gene
Although genetic factors contribute to about only five percent of
all breast cancer cases, they are a factor in approximately twenty-five
percent of all cases diagnosed where patients are under the age of
thirty.17 Because of this linkage, researchers have tried to isolate the
gene responsible and develop tests to allow the early identification of
those at high risk of inheriting this form of cancer. In late 1994, these
efforts culminated in the isolation of BRCA1, mutations of which
may increase susceptibility to breast and ovarian cancer. 18 In 1996,
researchers located BRCA2, a second breast cancer susceptibility
gene, on chromosome 13q.19 A large number of mutations to the
BRCA1 gene were soon described by an international group of
investigators.20 The groups making these discoveries patented both
the BRCA1 and BRCA2 genes as well as many of the mutations
causing susceptibility to breast and ovarian cancer. The events
occurring during the hunt for the BRCA1 gene, and its eventual
patenting, provide a useful insight into the position of those who
object to the way that DNA patenting is currently progressing.
Researchers, using genetic linkage techniques, first located a
breast cancer susceptibility gene in 1990.21 This involved a study of
the inheritance of polymorphisms22 through many generations of
307, 307 (1993).
16. See Huntington Disease Collaborative Research Group, A Novel Gene Containing a
Trinucleotide Repeat That Is Expanded and Unstable on Huntington's Disease Chromosomes, 72
CELL 971, 971 (1993).
17. See Yoshio Miki et al., A Strong Candidate for the Breast and Ovarian Cancer
Susceptibility Gene BRCA1, 266 SCIENCE 66, 66 (1994).
18. See Donna Shattuck-Eidens et al., A Collaborative Survey of 80 Mutations in the
BRCAI Breast and Ovarian Cancer Susceptibility Gene, 273 JAMA 535, 535 (1995) (describing
the structure of the BRCA1 gene).
19. See S.V. Tavtigian et al., The Complete BRCA2 Gene and Mutations in Chromosome
13q-linked Kindreds, 12 NATURE GENETICS 333, 333 (1996).
20. See Shattuck-Eidens et al., supra note 18, at 535-36.
21. See Hall et al., supra note 14, at 1684.
22. See NATIONAL RESEARCH COUNCIL, MAPPING AND SEQUENCING THE HUMAN
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families and the correlation of these polymorphisms with the
incidence of breast cancer in these families. 23 The initial location
placed the gene on chromosome 17q. However, it was not until 1993
that the gene was located to a region of one to two million bases of
DNA on this chromosome. 24 The availability of improved markers
eventually allowed the gene to be isolated to a region of 600,000
bases. 25 The isolation of the BRCA1 gene involved an international
collaboration of most of the groups involved in breast cancer linkage
analysis.26 A 1993 report by these groups summarized the results of
linkage studies performed on 214 families. These linkage studies
involved the use of a common set of markers and population
genealogies that were obtained from either cancer registries or
collaborating physicians.27
In late 1994, a team of scientists from Myriad Genetics, working
with groups at the University of Utah and the National Institutes of
Health (the "NIH"), succeeded in identifying and sequencing the
BRCA1 gene.28 Later, in 1996, Myriad scientists announced the
discovery of the BRCA2 gene, a second breast cancer susceptibility
gene, located on chromosome 13q.29 Myriad filed a patent application
covering the discovery of the BRCA1 sequences and eventually
obtained two DNA sequence patents, one claiming the sequence of
the BRCA1 gene itself, and the other claiming a number of harmful
mutations of this gene. 30
However, Myriad soon found itself involved in a legal battle with
OncorMed, Inc. over the rights to the BRCA1 gene. OncorMed had
been granted a patent covering a BRCA1 allele representing the most
likely BRCA1 sequence to be found in the majority of the normal
population. Although this sequence is very similar to the previously
disclosed Myriad sequence, it differs slightly because of the natural
GENOME 40-41 (1988) (describing a restriction fragment length polymorphism and its use in
linkage studies in mapping and sequencing the human genome).
23. See D.F. Easton et al., Genetic Linkage Analysis in Familial Breast and Ovarian Cancer:
Results from 214 Families, 52 AM. J. HUM. GENETICS 678, 678 (1993).
24. See Miki et al., supra note 17, at 66 (describing the isolation of BRCA1).
25. See id.
26. See Easton et al., supra note 23, at 678.
27. See, e.g., id. at 678-81.
28. See Miki et al., supra note 17, at 66.
29. See Tavtigian et al., supra note 19, at 333.
30. See United States Patent 5,747,282, dated May 5, 1998 (claiming the DNA sequence of
the BRCA1 gene); United States Patent 5,693,473, dated December 2, 1997 (claiming a number
of harmful mutations of the BRCA1 gene).
31. See United States Patent 5,654,155, dated August 7, 1997.
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occurrence of different polymorphisms of the normal BRCA1 gene.
Myriad and OncorMed sued each other, both parties claiming
infringement of their respective patents.3 In May 1998, the parties
settled this dispute. 33 Myriad gained exclusive rights to OncorMed's
patents for BRCA1 and BRCA2 for breast and ovarian cancer
genetic testing. OncorMed also agreed to cease offering BRCA1 and
BRCA2 genetic services. However, both parties retained diagnostic
and therapeutic rights to their respective patents.
Natural differences occurring between the DNA of individuals
result in many minor differences in the DNA sequence of a given
gene. 34  Hence, some criticized the granting of two such similar
patents.35 One researcher in the field complained that the whole
point of patent protection would be negated if every new variation of
a gene were allowed patent protection. Instead, the first discoverer of
a new gene should be given broad rights to ensure adequate
compensation for that discovery. 36 This is especially important for a
gene such as BRCA1. Researchers have identified at least eighty
different cancer susceptibility mutations to the BRCA1 gene.37 In
theory, a different group could have patented each of these
mutations. If normal noncancer susceptibility mutations of the gene
may also be patented, then a great number of patents could be
granted, each covering a slightly different version of the same gene.
Such a situation could either make the individual patents worthless
or, alternatively, cause a situation where multiple royalties
significantly increase the cost of any medical products produced using
the patented sequences.
A dispute concerning who should be named as inventors on the
BRCA1 patent arose when contributing scientists, working at the
NIH, were omitted from the original patent application covering the
BRCA1 gene sequence. 38 This dispute was eventually resolved with
32. See Eliot Marshall, The Battle over BRCA1 Goes to Court; BRCA2 May Be Next, 278
SCIENCE 1874, 1874 (1997).
33. See Myriad Genetics, Inc., Myriad Genetics Obtains OncorMed's BRCA1/BRCA2
Genetic Testing Program in Patent Settlement (visited June 29, 1999) <http://www.myriad.com/
pr/19980518.html>.
34. See SCHLEIF, supra note 1, at 227-31.
35. See Marshall, supra note 32, at 1847.
36. See id.
37. See Shattuck-Eidens et al., supra note 18, at 535.
38. See Helen Gavaghan, NIH Resolves Dispute on Cancer Gene Patent, 373 NATURE 649,
649 (1995).
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the inclusion of the NIH scientists as inventors.39 Myriad and its
licensee Eli Lilly & Co. retained exclusive worldwide rights to the
commercialization of the BRCA1 gene, although the NIH shares in
any revenue. But others involved in the search of the BRCA2 gene
objected to Myriad's BRCA2 sequence patent on the grounds that
other groups, which had contributed to the basic research necessary
to the isolation of the gene, were excluded.4° The patenting of the
gene also raised objections based on the fear that such patents make
diagnostic tests more expensive and discourage other scientists from
working in the area.
41
Myriad countered such arguments by claiming that DNA patents
are essential if biotechnology companies are to attract money for
risky development projects.42 The company pointed out that it had
invested millions of dollars in the development of a comprehensive
test for breast cancer susceptibility.43
B. Private and Public Genes- The Patentability of Expressed
Sequence Tags
Although the precise biological mechanism of action of the
BRCA1 and BRCA2 genes was not known when the Myriad patent
applications were filed, these applications did involve DNA coding
sequences for proteins of known biological effect. For example,
mutations in the BRCA1 gene were known to account for roughly
forty-five percent of inherited breast cancer and eighty to ninety
percent of families with increased risk of early onset breast and
ovarian cancer.44
However, it is possible to obtain and sequence expressed DNA
gene fragments without knowing the complete structure of the gene
from which they are derived or the biological function of the proteins
39. See id.
40. See Clive Cookson, Research into Breast Cancer Has Highlighted Concerns About the
Use of Information, FIN. TIMES, June 27, 1996, at 12, 12. The Director of the Cancer Research
Campaign, a United Kingdom charity, complained that, while the charity had contributed to
Myriad's efforts to determine the structure of BRCA1, its scientists were "suddenly shunned."
Id.
41. See Eliot Marshall, Rifkin's Latest Target: Genetic Testing, 272 SCIENCE 1094, 1094
(1996) (describing efforts by antibiotechnology activist Jeremy Rifkin to challenge the Myriad
BRCA1 patents). Some also complained that genes, like BRCA1 and BRCA2, are products of
nature and should not be patented. See id. For a discussion of Rifkin's concerns regarding the
biotechnology industry, see generally JEREMY RIFKIN, THE BIOTECH CENTURY (1998).
42. See Marshall, supra note 41, at 1094.
43. See id.
44. See Easton et al., supra note 23, at 678.
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coded by these sequences.45 One method of DNA sequencing, the
cDNA technique, uses messenger ribonucleic acids ("mRNAs"),
transcribed from DNA coding sequences, to produce complimentary
DNA ("cDNA"). These cDNAs, termed ESTs, are fragments
containing about 400 bases, corresponding to only part of an
expressed gene. 46 However, some point out that ESTs may be used as
probes, allowing expressed gene sequences to be identified without
searching the entire genome.
47
Research scientist J. Craig Venter, while working at the NIH,
developed an automated DNA sequencing method based on ESTs.
48
Venter claimed that his technique would allow expressed genes to be
sequenced quickly and at low cost. However, the publicly funded
HGP rejected this approach in favor of a genomic sequencing method
where the entire genome is sequenced, not just the approximately five
percent of DNA corresponding to expressed genes.49 Nevertheless, in
1992, the NIH filed patent applications for more than 2000 partial
gene sequences, which were determined using Venter's technique.50
This action caused much criticism from researchers involved with the
HGP. 1 Some criticized the applications on the grounds that the ESTs
did not meet the technical requirements for patentability. 2 Others
argued that, even if the ESTs did meet these requirements, patents on
ESTs would impede the open exchange of information on which the
HGP depended.53
The NIH later withdrew its EST applications,5 4 leaving the
45. See generally Mark D. Adams et al., Complementary DNA Sequencing: Expressed
Sequence Tags and Human Genome Project, 252 SCIENCE 1651, 1651-56 (1991).
46. See, e.g., Tim Beardsley, Piecemeal Patents: The U.S. Reconsiders Patents on DNA
Fragments, 267 SCI. AM. 107, 107 (1992).
47. See Glenn A. Friedrich, Moving Beyond the Genome Projects, 14 NATURE
BIOTECHNOLOGY 1234, 1234 (1996) (describing the relations between DNA sequencing
companies and their pharmaceutical company partners); see also Poste, supra note 6, at 534. It
is claimed that ESTs also have commercial value in diagnostic tests for altered gene expression
and as structural templates for oligonucleotide-based therapeutic agents. See id.
48. See Mark D. Adams et al., Sequence Identification of 2,375 Human Brain Genes, 355
NATURE 632, 632 (1992).
49. See NATIONAL RESEARCH COUNCIL, supra note 22, at 56-74.
50. See Bernadine Healy, Special Report on Gene Patenting, 327 NEW ENG. J. MED. 664,
665 (1992) (describing the reasons behind the NIH's decision to file the patent applications).
51. See Leslie Roberts, Genome Patent Fight Erupts, 254 SCIENCE 184, 184-86 (1991)
(describing attempts by the NIH to obtain patents on a large number of ESTs without knowing
the function of the gene fragments).
52. See id.
53. See id.
54. See Christopher Anderson, NIH Drops Bid for Gene Patents, 263 SCIENCE 909, 909
(1994).
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technical questions regarding their patentability unresolved.
However, the controversy surrounding the patentability of ESTs did
not disappear. While the HGP concentrated its efforts on the
sequencing of the entire human genome, privately funded
corporations put a higher priority on sequencing expressed genes.55
In 1992, Venter quit the NIH to head The Institute of Genome
Research ("TIGR"), a not for profit DNA sequencing center. TIGR
received its financial backing from Human Genome Sciences, Inc.
("HGS"), a privately funded, for profit corporation. By sequencing
ESTs, companies such as HGS were in a position to sequence entire
genes much faster than those using the conventional approach. A
consortium of HGS and TIGR, with $125 million in financial backing
from the pharmaceutical company SmithKline Beecham, amassed a
database containing a large number of ESTs.56 Concerns were
expressed regarding possible attempts by HGS to patent EST
sequences. In 1996, reports claimed that the consortium filed about
200 of the 450 applications for human gene patents.57
The issue of EST patenting became the focus of arguments
regarding the release of DNA sequence data. Some accused TIGR
and HGS of locking up their EST sequences and placing restrictions
on academic researchers in return for access to the HGS database. 58
In addition, some researchers believed that restrictions placed upon
the release of sequence data from the TIGR database would slow
down research on pathogenic organisms. 9 The movement supporting
the immediate release of sequence data culminated in a requirement
that laboratories receiving grants from the NIH release preliminary
human DNA sequence data quickly and without legal limitations.60
The pharmaceutical company Merck & Co., SmithKline Beecham's
55. See Eliot Marshall, A Showdown over Gene Fragments, 266 SCIENCE 208,208 (1994).
56. See id; Eliot Marshall, The Company That Genome Researchers Love to Hate, 266
SCIENCE 1800, 1800-01 (1994).
57. See Arthur L. Caplan & Jon Merz, Patenting Gene Sequences: Not in the Best Interests
of Science or Society, 312 BRIT. MED. J. 926, 926 (1996).
58. See Eliot Marshall, Is Data-Hoarding Slowing the Assault on Pathogens?, 275 SCIENCE
777, 777, 779 (1997).
59. See id.
60. See National Human Genome Research Institute, NHGRI Policy on Release of Human
Genomic Sequence Data (visited March 7, 1997) <http://www.nhgri.nih.gov/Grant-inf.. .g/
Statements/RFA/datarelease.html>; see also Eliot Marshall, Genome Researchers Take the
Pledge: Data Sharing, 272 SCIENCE 477, 477 (1996). The NIH also required that grantees notify
them as soon as they inform their own institutions that a discovery may be patentable. See id.
This policy has been extended to cover microbial genome sequences. See National Institutes of
Health, Data Release Policy: Microbial Genome Sequencing Projects (visited March 17, 1999)
<http://www.nih.gov/grants/guide/notice-files/ not99-040.html>.
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main competitor, also announced that it would finance a duplication
of the work already completed by HGS and TIGR, and that this data
would be available without restriction. In 1997, TIGR announced
that it had terminated its agreement with HGS and released its
database of over 600,000 ESTs.6' However, private corporations
continued to compile EST sequences. For example, Incyte claims
that it has an EST database consisting of three million EST
sequences, 2.3 million of which are of priority to Incyte itself.62 Incyte
also claims to have the ability to process 28,000 ESTs per day.
63
EST patentability issues resurfaced in early 1997 with an
announcement by the United States Patent and Trademark Office
(the "USPTO") that it would allow claims on ESTs based on their
utility as probes.64 At that time, reports claimed that at least 350 EST
patent applications, covering more than 500,000 sequences, were
pending at the USPTO.65 However, the USPTO also acted to limit
the number of sequences that could be claimed in any one application
to ten. Hence, applicants wishing to patent a large number of ESTs
would be required to file thousands of new applications. This greatly
increased the transaction costs involved in obtaining DNA sequence
patents.
Concerns remained about the possible impact of EST patents.
Some of the filed applications claimed not only the EST sequences
themselves, but also the complete sequences of the genes from which
the ESTs were derived as well as the proteins coded from these
genes.66 Even where this was not so, some believed that the rush to
make partial sequences public would undermine attempts to patent
the complete gene sequences when these were determined. The
USPTO added to these concerns by issuing a statement in 1998
stating that broad patent claims might be allowed for some ESTs.
67
Hence, claims for ESTs could, in some cases, give patent rights over a
later discovered complete gene sequence.
61. See Emma Dorey et al., TIGR Releases EST Data Publicly, 15 NATURE
BIOTECHNOLOGY 397, 397 (1997).
62. See Incyte Pharmaceuticals, Inc., LifeSeq (visited June 29, 1999)
<http://www.incyte.com/products/lifeseq/lifeseq.html>.
63. See Incyte Pharmaceuticals, Inc., Databases (visited June 29, 1999)
<http://www.incyte.com/products/databases.html>.
64. See Gene Fragments Patentable, Official Says, 275 SCIENCE 1055, 1055 (1997).
65. See Eliot Marshall, Companies Rush to Patent DNA, 275 SCIENCE 780, 781 (1997).
66. See Roberts, supra note 5, at 912-13.
67. See Dorothy R. Auth, Are ESTs Patentable?, 15 NATURE BIOTECHNOLOGY 911, 911
(1997); see also Ken Chahine, Patent Office Resurrects EST Debate, 16 NATURE
BIOTECHNOLOGY 711,711 (1998).
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Such a situation has caused great concern that those who finally
isolate a gene sequence would be required to pay royalties to the
patentee of any EST sequence contained in that gene. This situation
could slow the development of biotechnology, and it has caused many
to call for the limitation of EST claims.68 In late 1998, Incyte claimed
to have received the first U.S. patent for an EST.69 This patent claims
polynucleotides and a full-length gene that encodes for protein
kinases. However, the ESTs covered are unlike those in the original
NIH application in that they are highly characterized. The full-length
gene from which they are derived is identified, and its function is
known. Nevertheless, the granting of this patent again renewed fears
that overly broad proprietary rights would be granted to EST
sequences.7 0
In May 1998, the debate over privately funded sequencing was
renewed when Venter announced that he planned to form a new
company, Celera Genomics, for the purpose of "substantially"
sequencing the human genome in three years, at a cost of as little as
$300 million.71 The HGP's sequencing efforts are expected to cost ten
times more. Venter's efforts are backed by $200 million in funding
from Perkin-Elmer Corporation, the world's largest manufacturer of
automated sequencing instruments.7 2 He plans to use a technique,
whole-genome "shotgun" sequencing, which TIGR has used to
sequence several bacteria. The entire human genome will be broken
up into segments of no more than 5000 bases. These segments will
then be sequenced and assembled into the complete genome. The
HGP groups work with much smaller sequences. They first break the
genome up into sequences of 150,000 bases and then break each of
these sequences into smaller fragments for sequencing.
Venter's approach has its critics. Shotgun sequencing has been
68. See, e.g., Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation?:
The Anticommons in Biomedical Research, 280 SCIENCE 698, 698 (1998) (arguing for coherent
boundaries of upstream patents to minimize restrictive licensing practices that interfere with
product development).
69. See Tony Relchhardt, Patent on Gene Fragment Sends Researchers a Mixed Message,
396 NATURE 499, 499 (1998).
70. See id.
71. See Eliot Marshall & Elizabeth Pennisi, Hubris and the Human Genome, 280 SCIENCE
994, 994 (1998).
72. See Vicki Glaser, PE/TIGR Provokes Genome Sequencing Skeptics, 16 NATURE
BIOTECHNOLOGY 610, 610 (1998); see also James C. Mullikin & Amanda A. McMurray,
Sequencing the Genome, Fast, 283 SCIENCE 1867, 1867-68 (1999) (describing Perkin-Elmer's
ABI Prism 3700 DNA analyzer, which is to be used by Venter's company in the sequencing
efforts).
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considered before and rejected for a variety of reasons.73 Some claim
that assembly of the genome will present considerable difficulties.
Others complain that Venter's approach will leave more gaps in the
genome than will conventional sequencing methods. In addition,
others fear that Venter's group will attempt to patent their sequences.
Venter rejected this objection. He says that his company will only
patent 100 to 300 pharmacologically interesting genes, and thereafter
genes will be patented only when clear uses have been identified.
Partly to safeguard its claims, Celera intends to release sequence
information quarterly instead of on a daily basis, as many publicly
funded laboratories do. This approach has generated considerable
criticism.
Venter's entry into the race to sequence the human genome,
along with that of Incyte, has caused the HGP to reassess its goals and
plan for a "working draft" of the human genome, constructed using
shotgun sequencing, to be completed by 2001. 74 This deadline was
later advanced by eighteen months. 75 In addition, Celera and a HGP
group will join forces to sequence the genome of the fruit fly
Drosophila melanogaster, and discussions are underway of a joint
effort to sequence the human genome using whole-genome shotgun
sequencing.
76
The debate concerning the release of newly sequenced data
shows no sign of coming to an end. The patentability of Single
Nucleotide Polymorphisms ("SNPs") is considered by some to be
likely to cause similar debate as was raised by ESTs.7 7 SNPs are small
variations in the genetic code that occur approximately once every
1000 DNA bases along the three billion, DNA base human genome. 7
8
73. See Philip Green, Against a Whole-Genome Shotgun, 7 GENOME RES. 410, 410-16
(1997) (rejecting the use of whole-genome shotgun sequencing to sequence the human genome).
But see James L. Weber & Eugene W. Myers, Human Whole-Genome Shotgun Sequencing, 7
GENOME RES. 401, 401-06 (1997) (supporting the use of whole-genome shotgun sequencing to
sequence the human genome).
74. See Vicki Brower, Genome II: The Next Frontier, 16 NATURE BIOTECHNOLOGY 1004,
1004 (1998).
75. See Elizabeth Pennisi, Academic Sequencers Challenge Celera in a Sprint to the Finish,
283 SCIENCE 1822, 1822 (1999).
76. See Elizabeth Pennisi, Fruit Fly Researchers Sign Pact with Celera, 283 SCIENCE 767,
767 (1999).
77. See, e.g., "SNPs" Are Next Focus of Intellectual Property Debate Among Researchers, 60
"The Pink Sheet" (F-D-C REP.) 23 (May 18, 1998) [hereinafter Pink Sheet] (reporting that NIH
Director Harold Varmus considers that the patentability of SNPs is likely to be the next topic in
the debate regarding the patentability of research tools).
78. See Elizabeth Pennisi, A Closer Look at SNPs Suggests Difficulties, 281 SCIENCE 1787,
1787 (1998).
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A number of pharmaceutical companies are already reported to have
taken steps to obtain databases containing SNP information. 71 Calls
have been made for the immediate release of information in SNP
databases with unconditional access. However, many consider it
likely that at least some SNPs will be patented. 80
SNPs offer researchers a valuable method for identifying genes
associated with a given disease. They may be used in the same way as
genetic markers were used during the isolation of the BRCA genes.
Fears that SNPs could be patented have led to calls that a new
repository of SNP information be set up and that this information
should be freely available to the public.81 Recently, a partnership,
which was set up by large pharmaceutical companies, has announced
that it will spend $45 million to archive SNPs and make this
information freely available.82
II. THE PATENTABILITY OF DNA
The debate regarding the patentability of the BRCA genes and
ESTs has centered on two questions. Firstly, does the DNA involved
meet the statutory requirements for patentability? Secondly, even if
this is so, are there other ethical or policy reasons that should prevent
a patent from being granted?
A. The Statutory Requirements for Patentability
The first of these questions can be answered only after reviewing
the statutory requirements for patentability and discussing how these
standards have been applied. A U.S. patent confers a twenty-year
exclusive right 83 to prevent others from making, using, selling, offering
79. See Sylvia Davidson, Incyte SNPs Up Hexagen for New Firm, 16 NATURE
BIOTECHNOLOGY 895, 895 (1998) (discussing efforts by a consortium of companies to develop
SNP databases at a cost of $150 to $200 million); Eliot Marshall, Snipping Away at Genome
Patenting, 277 SCIENCE 1752, 1752 (1997) (discussing an agreement between Abbott
Laboratories and the genomics company Genset, where Abbott would gain rights to markets of
potential use in pinpointing genes involved in multi-gene diseases).
80. See Pink Sheet, supra note 77, at 23.
81. See Marshall, supra note 79, at 1752.
82. See Eliot Marshall, Drug Firms to Create Public Database of Genetic Mutations, 284
SCIENCE 406, 406 (1999).
83. Revisions in international trade laws in the General Agreement on Tariffs and Trade
have resulted in the term of a U.S. patent being changed to 20 years, measured from the date
the patent application is filed, rather than 17 years, measured from the date the patent is issued
by the United States Patent Office. See Uruguay Round Agreements Act, Pub. L. No. 103-465,
108 Stat. 4809 (codified as amended at 19 U.S.C. § 3501 (1994)).
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for sale, or importing the invention.84 A patent may be obtained for
certain classes of invention,85 including chemical compounds like
DNA molecules,86 only when particular statutory requirements are
met.
An invention must also have a known utility.87 It must achieve
some desired result and have at least some minimum social benefit.
Traditionally, the potential role of a chemical compound for drug
testing is not sufficient to meet the utility requirement. 88 Nor is the
fact that it can be used to make another compound sufficient to meet
the utility requirements unless some utility is shown for the final
compound.89 The BRCA genes would meet this requirement because
of their potential use in the diagnosis of breast cancer. However, the
utility of an EST is more questionable, especially if nothing is known
about the genes from which it is derived.
An invention must also be novel to be patentable. 90 The prior art
must not contain all the elements of the invention in a single
reference.91 In the case of a chemical compound, a chemical is not
novel if it is present in nature. 92 However, purified preparations of
naturally occurring biological products meet the novelty requirement
if the compound was not previously available in an isolated or
purified state and the purified product may be used in a way the
impure product could not.93 Purified partial and complete genes meet
this requirement because isolation and purification of the DNA
allows for uses that are not possible when the DNA is in its natural
state.
In addition, patent protection cannot be obtained for an obvious
84. See 35 U.S.C. § 154 (1997).
85. Patents are given to the inventor of "any new and useful process, machine,
manufacture, or composition of matter, or any new and useful improvement thereof." 35 U.S.C.
§ 101 (1994).
86. See Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991) (stating
that "[a] gene is a chemical compound, albeit a complex one"), cert. denied, 502 U.S. 856 (1991).
87. To be patentable, an invention must be "new and useful." 35 U.S.C. § 101.
8& See Brenner v. Manson, 383 U.S. 519, 534-35 (1966) (disallowing patent protection for a
novel process of manufacture of certain known steroids, which had no known utility).
89. See In re Application of Joly, 376 F.2d 906, 908 (C.C.P.A. 1967) (rejecting product and
process claims related to esters of 2-enols of steroids and the methods of their preparation on
the basis of insufficient disclosure of utility).
90. See 35 U.S.C. § 102 (1994).
91. See Diversitech Corp. v. Century Steps, Inc., 850 F.2d 675, 677 (Fed. Cir. 1988).
92. See Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 132 (1948).
93. See In re Application of Bergstrom, 427 F.2d 1394, 1400-02 (C.C.P.A. 1970) (allowing a
patent for purified prostaglandin although structurally identical impure compounds existed in
nature).
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invention.94 To determine whether an invention is obvious, the scope
and content of the prior art, the differences between the prior art and
the invention, and the level of ordinary skill in the pertinent art are
considered.95 Because of problems unique to chemicals, detailed
subrules have developed to determine the non-obviousness of
chemical inventions. 96  In particular, structural similarity between a
claimed compound and prior art compounds may create a showing of
prima facie obviousness."' If this is established, the burden of showing
non-obviousness then shifts to the patent applicant,98 and the burden
may be met by showing that the claimed compound has unexpectedly
improved properties over the prior art. 99 Hence, prima facie non-
obviousness for a DNA molecule depends on a lack of similarity
between the claimed molecule and DNA molecules previously
disclosed. If this is not present, the inventor must show that the
claimed DNA has unexpected properties.
Finally, the patent applicant must enable and supply a written
description of the invention. Historically, the written description
informed the public of what the inventor claimed as the invention.100
This function was distinct from enablement, which required that those
skilled in the art could use the invention without undue
experimentation. 10' However, more recently, the written description
requirement has been applied to require that the original patent
94. See 35 U.S.C. § 103 (1997). A patent will not be granted if the "differences between the
subject matter sought to be patented and the prior art are such that the subject matter as a
whole would have been obvious at the time the invention was made to a person having ordinary
skill in the art to which said subject matter pertains." Id. § 103(a).
95. See Graham v. John Deere Co., 383 U.S. 1, 17 (1966) (developing the four-part
obviousness test). The Graham court also suggested that secondary indications of obviousness,
such as commercial success, long felt but unsolved needs, or failure of others might be used to
"give light to the circumstances surrounding the origin of the subject matter sought to be
patented." Id. at 17-18.
96. See, e.g., Chris P. Konkol, The "Problem Solved" In Re Wright and In Re Dillon, 31
IDEA 131, 131-32 (1990); Helmuth A. Wegner, Prima Facie Obviousness of Chemical
Compounds, 6 AM. PAT. L. ASS'N Q. J. 271,271 (1978).
97. See In re Dillon, 919 F.2d 688, 692 (Fed. Cir. 1990) (en banc), cert. denied, 500 U.S. 904
(1991). Closely related homologs, analogs, and isomers may create prima facie obviousness.
See id. at 696.
98. See id. at 692.
99. See id.
100. See generally Janice M. Mueller, The Evolving Application of the Written Description
Requirement to Biotechnological Inventions, 13 BERKLEY TECH. L. J. 615 (1998) (describing the
historical development of the written description requirement).
101. See id. at 616-17; see also In re Application of Fisher, 427 F.2d 833, 836 (C.C.P.A. 1970).
Whereas compliance with the enablement standard is a matter of law, compliance with the
written description requirement is a matter of fact. See Fiers v. Revel, 984 F.2d 1164, 1170 (Fed.
Cir. 1993).
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claims are supported by sufficient detail so that new claims or
modifications to the original claims can be determined to be
encompassed by the original invention.10 2
The written description requirement'013 is not met unless the
specification describes the invention in sufficient detail so that one
skilled in the art would reasonably consider that the inventor was in
possession of the claimed subject matter. 10 4 In the case of a chemical
compound, the written description requirement may not be met even
though sufficient information is disclosed to enable one skilled in the
art to produce and use a claimed compound.105 The specification must
convey clearly to those skilled in the art that the inventor invented
that specific compound.106  Hence, the written description
requirement may be met by setting forth the chemical structure of a
compound.107  Alternatively, the requirement may be met by
describing sufficient properties of the compound that allow
predictability of the chemical structure by one skilled in the art. 0
B. The Application of Patentability Standards to DNA
The task of applying the statutory requirements to DNA has
fallen to the Court of Appeals for the Federal Circuit (the "Federal
Circuit"). So far, the Federal Circuit has applied the obviousness and
written description requirements to DNA in a way that allows those
who determine the complete structure of a gene to obtain patent
protection despite the previous disclosure of partial DNA sequences
from the gene. The court has also limited the scope of sequence
claims by placing requirements on the ways in which a DNA
sequence must be adequately described in the patent specification.
102. See In re Application of Ruschig, 379 F.2d 990, 994-95 (C.C.P.A. 1967).
103. The specification of a U.S. patent must contain "a written description of the invention,
and of the manner and process of making and using it, in such full, clear, concise, and exact
terms as to enable any person skilled in the art to which it pertains.., to make and use the
same." 35 U.S.C. § 112 (1994).
104. See Fiers, 984 F.2d at 1170.
105. See In re Application of Ahlbrecht, 435 F.2d 908, 911 (C.C.P.A. 1971).
106. See Ruschig, 379 F.2d at 996.
107. See Lockwood v. American Airlines, Inc., 107 F.3d 1565, 1572 (Fed. Cir. 1997).
108. See Kennecott Corp. v. Kyocera Int'l, Inc., 835 F.2d 1419, 1421 (Fed. Cir. 1987). In
Kennecott, a patent applicant originally disclosed "ceramic bodies" without disclosing their later
claimed "equiaxed microstructure" property. Id. at 1423. The Federal Circuit held that the
"equiaxed microstructure" property was supported by the original specification because such a
structure was an inherent property of the "ceramic bodies" originally disclosed. See id.
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1. Obviousness
The Federal Circuit has treated DNA as a chemical composition
and applied chemical case law based on structural similarity when
determining the non-obviousness of a DNA molecule.1°9 However,
because of the degeneracy of the genetic code,"0 where more than
one DNA sequence may code for a given protein, the court has held
that the prior art disclosure of a full or partial amino acid sequence
does not necessarily render the DNA sequence coding for that amino
acid sequence obvious.
In Deuel, the court found the existence of a general method of
isolating DNA molecules to be "essentially irrelevant" as to whether
the specific DNA molecules would have been obvious without other
prior art suggesting the claimed DNA molecules."' The court stated
that a case for obviousness is normally based on structural similarity
between the claimed compound and a prior art compound. "2 Thus,
the combination of a reference disclosing a partial amino acid
sequence for a protein together with a reference teaching a general
method of DNA cloning did not render DNA molecules coding for
the protein obvious."3 The redundancy of the genetic code meant
that a great number of possible DNA molecules could have coded for
the protein.114 Hence, there was no motivation to prepare the specific
DNA claimed. "5
Deuel has been criticized extensively for taking a standard of
obviousness suited to chemical compounds and mistakenly applying
that standard to the protein/DNA relationship." 6 According to this
rationale, it is wrong to treat DNA as a simple polymer of nucleic
109. See Amgen, 927 F.2d at 1207-09.
110. See SCHLEIF, supra note 1, at 183-218 (describing the process of protein synthesis).
Proteins comprise a chain of amino acids, 20 of which exist in nature. See id. at 150-51. Each
amino acid is coded for by a series of three DNA bases, called a "codon." See id. at 188-90.
More than one codon may code for a particular amino acid. See id. at 189.
111. In re Deuel, 51 F.3d 1552, 1559 (Fed. Cir. 1995).
112. See id. at 1558.
113. See id. at 1557.
114. See id. at 1158.
115. See id. at 1559. However, the court noted that for simple proteins of small size or
proteins lacking in redundancy each possible DNA may be obvious over the protein sequence.
See id. For example, a prior art genus of 20 compounds rendered every species within the genus
unpatentable. See id.
116. See, e.g., Anita Varma & David Abraham, DNA Is Different: Legal Obviousness and
the Balance Between Biotech Inventors and the Market, 9 HARV. J.L. & TECH. 53, 78-79 (1996).
Some argue that a "suggestion" test be applied to establish the elements of a prima facie case of
obviousness where less emphasis is given to the protein/DNA structural relationship. See id. at
78-84.
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acids because, unlike traditional polymers, minor changes in the base
structure of DNA can produce major changes in function.117 Deuel
has also been criticized for effectively ignoring the non-obviousness
standard and awarding patent protection where the methods available
to determine the structure of the DNAs were "obvious to try" and
were performed with a "reasonable expectation of success."118
However, the criticism of the Deuel decision has not been
universal. Many in the biotechnology industry support the decision as
giving necessary protection to new biotechnology inventions.11 9 Even
some that are critical of the Deuel outcome have recognized that the
court had little alternative if it wanted to protect new products and
prevent damage to the growth of the industry. 20 They claim that
Deuel allows those who isolate DNA sequences using "routine"
methods to obtain patents for their inventions; this encourages
further research. The holding also allows those who determine the
complete structure of a gene to obtain patent protection although the
DNA sequence of a small part of the gene was present in the prior
art.
2. Written Description
In Fiers v. Revel, when determining whether an inventor had
conceived 2' a DNA sequence, the Federal Circuit held that the
conception of DNA, like the conception of any other chemical,
required a definition of the molecule other than by its functional
utility.122 Conception does not occur until the inventor has "a mental
picture of the structure of the chemical, or is able to define it by its
method of preparation, its physical or chemical properties, or
whatever characteristics sufficiently distinguish it. ' ' 123 Definition of
the compound by its principal biological property is not sufficient.
24
117. See id. at 67-68.
118. Philippe Ducor, The Federal Circuit and In Re Deuel: Does § 103 Apply to Naturally
Occurring DNA?, 77 J. PAT. & TRADEMARK OFF. Soc'Y 871,889-890 (1995).
119. See, e.g., D.D., U.S. Court Rules Discovery of Gene Sequence "Not Obvious," 375
NATURE 94, 94 (1995) (reporting on the response of the Biotechnology Industry Association to
the Deuel decision).
120. See Ducor, supra note 118, at 898.
121. Conception of an invention requires the "formation in the mind of the inventor, of a
definite and permanent idea of the complete and operative invention, as it is hereafter to be
applied in practice." Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed.
Cir. 1986), cert. denied, 480 U.S. 947 (1987).
122. See Fiers, 984 F.2d at 1169.
123. Id. (quoting Amgen, 927 F.2d at 1206).
124. See id. at 1168-69.
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If conception of a DNA molecule requires a precise definition, then
the written description also requires such specificity.25 The court also
rejected a requirement that conception of a DNA molecule requires
knowledge of the DNA sequence only where isolation of the DNA is
difficult. 126  The sequence must be disclosed irrespective of the
difficulty of the method of isolation of the DNA.
In Regents of the University of California v. Eli Lilly & Co., the
court again addressed the issue of the written description required to
support claims directed at cDNA sequences. 2 7  A claim for an
organism containing cDNA coding for human insulin was held invalid
for lack of an adequate written description.125 Although the
specification contained a general method for obtaining human cDNA
along with the amino acid sequences for human insulin, no
information regarding the cDNA's structural or physical features was
present. 29 Because the cDNA was not described in the patent
disclosure, the written description was inadequate.13 0
Some criticize the decision in Eli Lilly as involving a significant
deviation from the status quo and a heightening of the patentability
requirements for biotechnological inventions."' In addition, the
requirement that the DNA structure be disclosed is criticized as
placing an unnecessary restriction on the manner in which the
compound may be described.12  Some also consider that, while the
decision will not affect recently filed patents, many patent rights
secured by early pioneers in the field may be ruled as invalid. 33
However, Eli Lilly does limit the breadth of DNA sequence claims.
In doing so, the decision prevents inventors from overreaching by
claiming more than they have disclosed. This is especially important
in the case of ESTs because disclosure of an EST sequence may be
125. See id. at 1171.
126. See id. at 1168. The defendant in Fiers argued that the examiner had incorrectly
interpreted Amgen as requiring that conception required knowledge of the DNA in all cases.
See id. In particular, the defendant claimed that Amgen was distinguishable because of the
great difficulty in determining the DNA sequence in that particular situation. See id. In
contrast, the defendant claimed that his method of determining DNA sequences could have
been easily carried out by one of ordinary skill in the art. See id.
127. Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1562 (Fed. Cir. 1997).
128. See id. at 1567.
129. See id.
130. See id.
131. See, e.g., Mueller, supra note 100, at 615.
132. See id. at 633.
133. See Harris A. Pitlick, The Mutation on the Description Requirement Gene, 80 J. PAT. &
TRADEMARK OFF. SOC'Y 209,222-23 (1998).
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followed by an attempt to claim the full gene from which the EST is
derived. The decision also limits the breadth of claims for full gene
sequences. In the case of a gene such as BRCA1, the disclosure of a
particular sequence will not allow the inventor to claim mutations of
the gene.
III. THE PRESENT STATUS OF DNA PATENTABILITY
The establishment of standards for the written description and
non-obviousness of DNA sequences has resulted in greater
predictability in the requirements that must be met before these
sequences may be patented. For example, when the full DNA
sequence for a protein of known utility is known, patent protection
may be obtained if the other statutory requirements are met.
Although many other issues remain to be resolved regarding attempts
to patent DNA sequences, the present standards do provide a basis to
examine the concerns surrounding the BRCA and EST issues.
A. BRCA Mutations-Multiple Patents on a Single Gene
The issues surrounding the patenting of the BRCA genes center
on two questions. The first concerns at what stage of the
development process should patent protection be given. The second
issue involves the breadth of patent protection given. Should a
mutation of a gene that is already in the public domain be patentable?
Myriad obtained a patent on the BRCA1 sequence because it
was the first to describe the complete DNA sequence of the gene.
Such an outcome is clearly in line with Eli Lilly, but is criticized
because no reward is available for those who contributed at an earlier
stage on the isolation of the gene. Such contributions may range from
genetic linkage studies that allowed the initial location of the gene to
a specific region of a particular chromosome to the development of
SNPs or ESTs used in the final isolation of the gene. However, if
patent protection is available for an EST corresponding to a fragment
of the BRCA1 gene, or a SNP that is shown to be correlated to the
incidence of breast cancer, this would not be so. In addition, claims
limited to the sequence disclosed, as required by Eli Lilly, would
allow for patent protection for the later disclosed complete gene
sequence.
In view of the holding in Deuel, it is unlikely that a full-length
gene sequence would be considered obvious on the basis of its
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structural similarity to a single EST sequence that was not previously
identified with that specific gene. It would be impossible to predict
the entire gene structure from such a sequence. However, when
multiple ESTs belonging to the same gene have been previously
disclosed, there may come a point when the full gene sequence is
considered as being obvious in light of the EST sequences.134 This is
even more likely to be the case where there is some suggestion in the
prior art that one or more ESTs were associated with the complete
gene.
Despite the holding in Deuel, the previous disclosure of a
complete gene sequence may make a mutation of the gene prima
facie obvious. However, even if this is so, non-obviousness can be
demonstrated by showing unexpected properties of the mutated gene,
such as a correlation to disease susceptibility. Hence, patent
protection for a mutation is supported when the mutation is related to
a disease state. In the case of harmful BRCA mutations, which are
shown to be correlated to the incidence of breast cancer, non-
obviousness is clearly supported.
Patent protection for nonharmful mutations that are present in
the "normal" population is more difficult to support. However, the
OncorMed patent covering a "consensus normal DNA sequence"
stated that, by allowing naturally occurring nonharmful mutations to
be identified, this sequence offered greater accuracy and reliability
for genetic testing than did the previously disclosed Myriad BRCA1
sequence. Here, the advantages offered by the OncorMed sequence
clearly overcame any presumption of obviousness due to structural
similarity between the two sequences.
The case law developed by the Federal Circuit in its application
of the statutory requirements for patentability clearly allow for
multiple patents to be granted on a single gene. As has occurred with
the BRCA1 gene, different inventors may obtain patents on
sequences differing only slightly. Such a situation is likely to lead to
more litigation like that which occurred between Myriad and
OncorMed. However, these situations may be resolved by cross-
licensing agreements between the holders of the patents, as occurred
here. The alternative is to grant broad patent protection to the
inventor who first isolates a gene and then hold all mutations to this
gene obvious. This would be an unacceptable alternative because it
134. This could be so independently of whether patents were obtained for the EST
sequences.
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would not provide incentives for inventors to pursue further research.
B. The Patentability of Expressed Sequence Tags
As stated previously, many consider ESTs to have great
commercial value because they may be used to help isolate the full
gene sequence.135 However, objections to the patentability of ESTs
have centered on claims that they lack utility.136 Recently, as a result
of the decisions in Eli Lilly and Fiers, the USPTO has announced that
patents directed at ESTs will be examined.'37  If such patent
applications are granted, it is possible that the Federal Circuit will
eventually have the opportunity to resolve long-standing differences
regarding whether ESTs meet the utility requirement.138
Claimed utilities for an EST include its use as a diagnostic
marker for the gene of which it is a part.'39 However, until this gene is
identified and shown to have a practical utility, patent protection for
such ESTs may not be allowed. 14° But an EST may also be used to
isolate a complete gene, and this function may provide the utility
necessary for patentability of an EST derived from an unidentified
gene. Thus, the question of EST utility depends on the particular
facts of the application in question. If, as in the case of the Incyte
"EST" patent, the full sequence of the corresponding gene is known
as well as the function of the protein coding from this gene, the utility
135. See, e.g., Marshall, supra note 55, at 208 (discussing databases of DNA fragments
compiled by private concerns with the hope that these sequences will be useful in identifying
disease genes and mapping active sites on the human genome).
136. See, e.g., Leslie Roberts, Top HHS Lawyer Seeks to Block NIH, 258 SCIENCE 209, 209
(1992).
137. See John J. Doll, The Patenting of DNA, 280 SCIENCE, 689, 690 (1998) (stating that the
USPTO views the examination of patent applications for ESTs and SNPs as analogous to any
other invention); see also Vincent Kiernan, Furore in U.S. over Patents for "Bit Part" DNA,
NEW SCIENTIST, Feb. 22, 1997, at 11, 11.
138. See Thomas D. Kiley, Patents on Random Complementary DNA Fragments?, 257
SCIENCE 915, 915-17 (1992). Kiley argues that the NIH's EST patent application was an attempt
to obtain control over the "raw material of scientific experimentation before research has
determined the practical value of such material." Id. at 915. Similarly, Poste argues that
"[o]pposition to the patenting of genomic inventions threatens to erode the foundation of
intellectual property rights needed to convert innovative research into new drugs, vaccines and
diagnostic tests." Poste, supra note 6, at 534.
139. For a detailed discussion of the NIH's EST patent application and an opinion regarding
the patentability of the disclosed DNA fragments, see Rebecca S. Eisenberg & Robert P.
Merges, Opinion Letter as to the Patentability of Certain Inventions Associated with the
Identification of Partial cDNA Sequences, 23 AIPLA Q. J. 1, 13-14 (1995).
140. See Brenner, 383 U.S. at 535 (stating that a compound does not meet the utility
requirement by being used in research concerning another compound unless the later
compound has a known utility).
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requirement will almost certainly be found to be met. However, if no
information regarding the nature of the complete gene is available, an
EST could be considered as being a chemical intermediate for a
compound with no known function. In such a situation, precedent
would suggest that the EST is not patentable. Nevertheless,
supporters of gene patenting have argued that, because such ESTs are
sold commercially as tools for the identification of complete genes,
14
they have an immediate benefit and should be subject to patent
protection even if the function of these genes is unknown.
142
However, even accepting that a library of ESTs has commercial value,
some sequences in the library are likely to be valuable as markers and
some are not. If no indication of the proven utility of a particular
sequence is disclosed, a significant amount of experimentation is still
required to determine the ultimate utility of that sequence. This may
preclude the granting of patent rights and provide a mechanism to
protect against premature claims.
If patent protection is granted to particular EST sequences, the
scope of this protection must be determined. The USPTO's view is
that broad sequence claims for ESTs may be supported.1 43 Given the
Federal Circuit's reluctance to uphold broad DNA patent claims in
Eli Lilly, it is likely that the court will reject such broad EST claims.
144
However, such a decision is likely to be years away; until then, much
uncertainty will remain as to the proper scope of EST patent
protection. Although those involved in testing for mutations of a
gene may prevent infringement by avoiding a patented EST sequence
or by altering the sequence in the EST region, the risk of multiple
damages may have a chilling effect on future biotechnology product
development.
The patentability of SNPs1 45 is likely to cause similar debate as
was raised by ESTs. 46 A number of pharmaceutical companies are
already reported to have taken steps to obtain databases containing
141. See, e.g., Jon Cohen, The Genomics Gamble, 275 SCIENCE 767, 771 (1997). For a report
on the $125 million agreement between SmithKline Beecham and HGS, which will allow
SmithKline Beecham access to HGS's database of DNA sequences, see id. at 768.
142. See, e.g., Poste, supra note 6, at 534-36 (arguing that ESTs have commercial value in
diagnostic tests for altered gene expression in disease states).
143. See Chahine, supra note 67, at 711.
144. See id.
145. SNPs are single base variations in the genetic code that occur approximately once every
1000 bases along the three-billion-base human genome. See Elizabeth Pennisi, A Closer Look at
SNPs Suggests Difficulties, 281 SCIENCE 1787, 1787 (1998).
146. See Pink Sheet, supra note 77, at 23-24.
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SNP information. 147  Such information may provide a means of
locating genes causing disease susceptibility in the same way that the
BRCA genes were isolated. Calls have been made for the immediate
release of information in SNP databases with unconditional access;
however, many consider it likely that at least some SNPs will be
patented.
148
Although some SNPs may be of great value because they
represent important mutations that may be used to identify either
those persons susceptible to particular diseases, or those who will best
respond to a given therapy, others are likely to be useless. 149 Hence,
attempts to patent SNP sequences raise the same problems of utility
as do attempts to patent ESTs. Unless a particular SNP is shown to
have a definite utility, the sequence does not meet the requirements
for patentability. Such utility may be shown if the sequence is linked
to a specific disease or is shown to be expressed in such a proportion
of the general population to make it useful in some other way.
In addition to questions of utility, a claim for a SNP sequence
may be rejected if the sequence is obvious in view of a prior art
sequence. For example, if the DNA sequence coding for a particular
protein is in the prior art, a sequence corresponding to a similar
protein with one amino acid different may be considered as being
prima facie obvious. 150 However, such a finding may be rebutted if it
is shown that the claimed sequence shows "unexpected results" by the
establishment -that differences in properties are of some practical
advantage.5 ' Although the presence of the sequence at a high
frequency in the general population may not be sufficient to establish
non-obviousness, the identification of a specific disease or
susceptibility of a particular form of therapy with the mutation is
more likely to rebut the initial showing of obviousness.'52
147. See Davidson, supra note 79, at 895; Marshall, supra note 79, at 1752-53.
148. See Pink Sheet, supra note 77, at 23.
149. See id.
150. The U.S. Patent and Trademark Office Board of Patent Appeals and Interference has
rejected a DNA coding for h-Interleukin-3 as obvious in view of a prior art DNA having a single
amino acid substitution at a single position. See Ex parte Anderson, 30 U.S.P.O.2d 1866, 1869-
70 (1993). The board's decision specifically noted that the substitution did not produce a
significant change in the chemical composition of the molecule. See id. at 1869. In addition, the
board rejected the claim that the chemical properties of the invention differed from the prior art
simply because it was present at a high frequency in the general population. See id. at 1870.
151. See id. at 1869.
152. See id. at 1969-70.
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IV. Do DNA SEQUENCE PATENTS PROMOTE NEW PRODUCT
DEVELOPMENT?
Even if DNA meets the statutory requirements for patentability,
some argue that, at least for some forms of DNA, patent protection
should not be granted. Such objections have taken a variety of forms.
Many raise the concern that, particularly in the biotechnology area,
the granting of patents with broad claims and the "stacking" of patent
royalties will inhibit research and slow the development of new
products. 153 These objections are not specific to the patenting of
DNA sequences, but have been raised in many other areas of
biotechnology.154 Others limit objections to the patenting of specific
forms of DNA, like ESTs and SNPs, on the basis that such patents
will inhibit scientific progress by limiting cooperation between
researchers. Finally, some researchers claim that, because of the
unique nature of the international cooperation involved in the HGP,
patent protection should not be granted for human DNA sequences.
In their widest form, objections to the patenting of the results of
"basic" research raise the concern that these patents may have a
stifling effect on the downstream development of products based
upon this research. 155  Such concerns are said to be particularly
relevant when the research leads to multiple owners of patent rights,
resulting in overlapping patent claims. Alternatively, the existence of
multiple patents, each covering a different aspect of a biotechnology
product, may result in the stacking of patent licenses, leading to
significant increases in the cost of the final product. These concerns
are relevant to DNA patents in a number of areas. For example,
conflicting rights and the stacking of royalties may occur if patents are
granted for multiple ESTs present in the same gene. This is especially
true if broad EST patents allow those who patent an EST to obtain
patent rights over the full gene. In addition, even if a complete gene
is patented, others may obtain patents for slightly different forms of
the same gene, as happened with the BRCA1 gene.
However, assuming that the patent concept does contribute to
scientific innovation and offers benefits to society, patent protection
153. See Richard Stone, Sweeping Patents Put Biotech Companies on the Warpath, 268
SCIENCE 656, 657 (1995) (discussing the response to the granting of a patent covering all forms
of genetically engineered cotton).
154. See Melvin Blecher, Dominating Patents: A View from the Bridge, 34 CLINICAL
CHEMISTRY 1705, 1705-08 (1988) (reviewing the response of the immunodiagnostics industry to
broad patents).
155. See Heller & Eisenberg, supra note 68, at 698.
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must start at some stage. With the BRCA genes, the identification of
the gene sequence was the chosen boundary. Here, upstream
property rights were limited. The final reward went to Myriad
because of the isolation of the BRCA genes. The objections raised
here went to the lack of reward to those who were involved in the
early stages of the search for the genes. Neither those who
contributed the DNA samples necessary for the initial linkage studies
nor those who performed the initial work on isolating the gene were
rewarded with property rights in the final test.
Two alternative solutions are available in a situation such as that
which occurred with BRCA1. First, patent rights could be withheld.
This could perhaps be justified on the grounds that the public
provided the samples that made the isolation of the gene possible.
Also, because significant public funding was provided to those
involved in the linkage studies, the withholding of patent rights is
justified because the public has already "paid" for the invention.
However, this viewpoint ignores the reality that Myriad succeeded
partly because of its superior funding. This funding was provided
based on the availability of patent protection for the products
developed. If such protection is not available, small biotechnology
companies such as Myriad are unlikely to be successful when
competing against larger players with superior production,
distribution and marketing resources.
The other alternative is to reward those who contributed earlier
in the race to isolate the BRCA genes. From the point of view of
fairness, this is an attractive option. However, the arguments raised
by the patenting of research tools would apply in this situation. This
approach also ignores the fact that many groups were engaged in a
race to identify the gene. Some, including Myriad, were motivated by
the prospect of obtaining intellectual property rights. To give rights
to all involved negates the purpose of the patent system. Those
objecting to the granting of similar DNA sequence patents to Myriad
and OncorMed raise this argument. If sequence patents are narrow
and easy to circumvent, they are probably not worth much. Narrow
property rights are unlikely to result in the funding necessary to
provide new biotechnology products.
Such arguments have additional force when applied to the
patentability of ESTs. Here, even if one assumes that publicly funded
sequencing efforts should not apply for patent protection, private
efforts by companies such as TIGR and Incyte have contributed
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significantly to advances in sequencing technology. These efforts
have caused the HGP to refocus its efforts, leading to plans for a
more efficient and faster sequencing of the human genome. Without
the private funding, obtained on the promise of future patent
protection, those innovations would not have been possible. This
factor strongly supports a claim that for DNA sequences the patent
system is achieving its primary aim of promoting new innovation.
Questions remain about the stage at which patent protection
should be given and to the appropriate breadth of that protection.
Clearly, a patent application like the NIH's EST application raises
many concerns. However, this application is by no means typical.
Although a final determination as to the patentability of the
sequences was not made, serious doubts exist because of a lack of
utility. In addition, because of restriction requirements placed on the
number of sequences from different genes that may be claimed in one
application, future applications claiming such a great number of
sequences could be split into numerous applications, greatly
increasing the cost to the applicant. This factor by itself is likely to
significantly reduce applications containing many unrelated
sequences of uncertain utility. Hence, as applied to ESTs, the present
patentability requirements offer an adequate solution to the problem
of promoting invention by creating incentive without offering patent
protection at too early a stage.
The rules developed by the Federal Circuit also provide a
suitable framework for determining the appropriate breadth of patent
protection. In the case of ESTs, application of the written description
requirement will likely result in claims being limited to the EST
sequence itself when the full gene structure is not disclosed. In
addition, under Deuel, incentive remains for those who go on to
discover the structure of the complete gene. When a complete gene,
such as BRCA1, is patented, protection against trivial sequence
changes should be given. Also, subsequently discovered mutations
that provide the basis for improved diagnostic or therapeutic products
should be protected.
CONCLUSIONS
Attempts to fit DNA sequence claims into the conventional
patentability framework developed for chemicals have raised
questions as to whether these criteria are applicable to DNA.
Despite this, over the past ten years, no new patentability rules have
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been developed for application to DNA sequences. Instead, DNA
patentability issues, such as those raised surrounding the BRCA
genes and ESTs, are in the process of being resolved using
conventional patentability criteria.
Many issues remain, particularly regarding ESTs, but questions
regarding utility look likely to be resolved on a case-by-case basis.
The questions to be answered involve the breadth of claims allowed
for ESTs rather than whether protection should be given. Private
funding, attracted by the prospect of profitable new products, has
played an important part in the success of sequencing efforts, and
there are strong indications that this will be even more so in the
future. Such funding probably would not be available without a
strong patent system.
A strong argument can be made for the immediate release of
sequence data generated by publicly funded organizations. These
organizations have often taken this approach and, in many cases, not
applied for patent protection. However, such requirements should
not be imposed upon the private sector. A strong patent system is
essential for the development of biotechnology. Nothing suggests
that the situation is any different in regard to the specific issue of
DNA sequence patents.

